Pages that link to "Q28834529"

The following pages link to Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling (Q28834529):

Displaying 28 items.

• JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. (Q38796883) (← links)
• Melatonin signaling in T cells: Functions and applications (Q39115619) (← links)
• JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics (Q39142126) (← links)
• Mechanisms and consequences of Jak-STAT signaling in the immune system. (Q39190119) (← links)
• Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8(+) T Cells (Q39448304) (← links)
• Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket (Q41835379) (← links)
• Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells. (Q46105618) (← links)
• Cutting Edge: IL-2-Induced Expression of the Amino Acid Transporters SLC1A5 and CD98 Is a Prerequisite for NKG2D-Mediated Activation of Human NK Cells. (Q46696952) (← links)
• IL-2 Modulates the TCR Signaling Threshold for CD8 but Not CD4 T Cell Proliferation on a Single-Cell Level (Q46768284) (← links)
• IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells. (Q47273387) (← links)
• JAK inhibition as a therapeutic strategy for immune and inflammatory diseases (Q47439880) (← links)
• Cytokines in Cancer Immunotherapy (Q47443294) (← links)
• Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis (Q48297847) (← links)
• JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. (Q48556502) (← links)
• The Common Cytokine Receptor γ Chain Family of Cytokines (Q50077079) (← links)
• Immunology: JAK3 inhibition—is it sufficient? (Q51553371) (← links)
• Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. (Q52603858) (← links)
• Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. (Q52626728) (← links)
• Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A (Q58614403) (← links)
• Natural Killer Cells: Development, Maturation, and Clinical Utilization (Q58785734) (← links)
• Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain (Q60047595) (← links)
• Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL (Q89777316) (← links)
• Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials (Q90645442) (← links)
• From stability to dynamics: understanding molecular mechanisms of regulatory T cells through Foxp3 transcriptional dynamics (Q90750401) (← links)
• Biology and regulation of IL-2: from molecular mechanisms to human therapy (Q90841499) (← links)
• Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) (Q91391227) (← links)
• Adaptation by naïve CD4+ T cells to self-antigen-dependent TCR signaling induces functional heterogeneity and tolerance (Q91721686) (← links)
• On the Way to Become a Natural Killer Cell (Q92712522) (← links)